Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Application of a new informatics tool for contamination screening in the HIV sequencing laboratory.

Ebbert MT, Mallory MA, Wilson AR, Dooley SK, Hillyard DR.

J Clin Virol. 2013 Jul;57(3):249-53. doi: 10.1016/j.jcv.2013.03.013. Epub 2013 Apr 11.

PMID:
23583427
2.

Development and evaluation of an assay for HIV-1 protease and reverse transcriptase drug resistance genotyping of all major group-M subtypes.

Aitken SC, Kliphuis A, Wallis CL, Chu ML, Fillekes Q, Barth R, Stevens W, Rinke de Wit TF, Schuurman R.

J Clin Virol. 2012 May;54(1):21-5. doi: 10.1016/j.jcv.2012.01.010. Epub 2012 Feb 3.

PMID:
22306272
3.

Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.

Pattery T, Verlinden Y, De Wolf H, Nauwelaers D, Van Baelen K, Van Houtte M, Mc Kenna P, Villacian J.

Intervirology. 2012;55(2):138-46. doi: 10.1159/000332013. Epub 2012 Jan 24.

PMID:
22286884
4.

HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.

Cardoso LP, Queiroz BB, Stefani MM.

J Clin Virol. 2009 Oct;46(2):134-9. doi: 10.1016/j.jcv.2009.07.009. Epub 2009 Aug 13.

PMID:
19682948
5.

Phylogenetic internal control for HIV-1 genotypic antiretroviral testing.

Boeri E, Canducci F, Grasso MA, Presi S, Carrera P, Racca S, Clementi M.

New Microbiol. 2004 Apr;27(2 Suppl 1):105-9.

PMID:
15646072
6.

Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.

Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, Rock D, Falloon J, Davey RT Jr, Dewar RL, Metcalf JA, Hammer S, Mellors JW, Coffin JM.

J Clin Microbiol. 2005 Jan;43(1):406-13.

7.

Discrepancies of HIV-1 reverse transcriptase resistance interpretation of insertions and deletions between two genotypic algorithms.

López-Lopes GI, Lança AM, de Paula Ferreira JL, Souza LO, de Macedo Brígido LF.

Intervirology. 2013;56(4):217-23. doi: 10.1159/000348511. Epub 2013 May 9.

PMID:
23689813
8.

Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.

Muñoz M, Carmona R, Pérez-Alvarez L, Cilla G, Suarez MD, Delgado E, Contreras G, Corral J, de Goicoetxea MJ, Medrano L, Lezaún MJ, Nájera R; Spanish Group for Antiretroviral Resistance Studies in Basque Country.

J Clin Virol. 2005 Jul;33(3):224-9. Epub 2005 Jan 12.

PMID:
15911444
9.

HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.

Aulicino PC, Rocco CA, Mecikovsky D, Bologna R, Mangano A, Sen L.

Antivir Ther. 2010;15(4):641-50. doi: 10.3851/IMP1571.

PMID:
20587857
10.

Sources and magnitude of intralaboratory variability in a sequence-based genotypic assay for human immunodeficiency virus type 1 drug resistance.

Galli RA, Sattha B, Wynhoven B, O'Shaughnessy MV, Harrigan PR.

J Clin Microbiol. 2003 Jul;41(7):2900-7.

11.

Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.

Kandathil AJ, Kannangai R, Verghese VP, Pulimood SA, Rupali P, Sridharan G, Grant P, Pillay D, Abraham OC.

Indian J Med Microbiol. 2009 Jul-Sep;27(3):231-6. doi: 10.4103/0255-0857.53205.

12.

Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory.

Avidor B, Girshengorn S, Matus N, Talio H, Achsanov S, Zeldis I, Fratty IS, Katchman E, Brosh-Nissimov T, Hassin D, Alon D, Bentwich Z, Yust I, Amit S, Forer R, Vulih Shultsman I, Turner D.

J Clin Microbiol. 2013 Mar;51(3):880-6. doi: 10.1128/JCM.02652-12. Epub 2013 Jan 2.

13.

An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing.

Simen BB, Braverman MS, Abbate I, Aerssens J, Bidet Y, Bouchez O, Gabriel C, Izopet J, Kessler HH, Stelzl E, Di Giallonardo F, Schlapbach R, Radonic A, Paredes R, Recordon-Pinson P, Sakwa J, St John EP, Schmitz-Agheguian GG, Metzner KJ, Däumer MP; 454 HIV Alphastudy Group.

J Virol Methods. 2014 Aug;204:31-7. doi: 10.1016/j.jviromet.2014.04.007. Epub 2014 Apr 13.

PMID:
24731928
14.
15.

Prevalence of drug resistance mutations and non-B subtypes in newly diagnosed HIV-1 patients in Denmark.

Jørgensen LB, Christensen MB, Gerstoft J, Mathiesen LR, Obel N, Pedersen C, Nielsen H, Nielsen C.

Scand J Infect Dis. 2003;35(11-12):800-7.

PMID:
14723353
16.

Surveillance of HIV drug resistance transmission in Iran: experience gained from a pilot study.

Mousavi SM, Hamkar R, Gouya MM, Safaie A, Zahraei SM, Yazdani Z, Asbaghi Namini S, Bertagnolio S, Sutherland D, Sandstrom P, Brooks J.

Arch Virol. 2010 Mar;155(3):329-34. doi: 10.1007/s00705-009-0583-6. Epub 2010 Jan 6.

PMID:
20052598
18.

Moderate prevalence of transmitted drug resistance and high HIV-1 genetic diversity in patients from Mato Grosso State, Central Western Brazil.

Ferreira AS, Cardoso LP, Stefani MM.

J Med Virol. 2011 Aug;83(8):1301-7. doi: 10.1002/jmv.22128.

PMID:
21678433
19.

Low prevalence of transmitted drug resistance among newly diagnosed HIV-1 patients in Latvia.

Balode D, Westman M, Kolupajeva T, Rozentale B, Albert J.

J Med Virol. 2010 Dec;82(12):2013-8. doi: 10.1002/jmv.21921.

PMID:
20981787
Items per page

Supplemental Content

Write to the Help Desk